

# Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy

NCT07461441

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Yeungnam University College of Medicine
Enrollment	50 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- Potential participants are eligible to be included in the study only if all of the following criteria apply:
- \[Ocular Conditions\]
- Presence of active polypoidal lesions in the macula as shown by Indocyanine green angiography (ICGA) AND presence of serosanguinous maculopathy, i.e., exudative or hemorrhagic features involving the macula on color fundus photography (CFP), FA and spectral domain optical coherence tomography (SD-OCT) AND presence of IRF or SRF that affects the central subfield as seen by SD-OCT.
- BCVA score must be d 78 and e 24 letters at 4 meters starting distance using early treatment diabetic retinopathy study (ETDRS) visual acuity charts at both Screening and Baseline.
- Greatest liner dimension (GLD) of the total lesion area (branching vascular network \[BVN\] + polypoidal lesion)  $< 5400 \mu\text{m}^2$  (equivalent to 9 macular photocoagulation study \[MPS\] Disc Area) as delineated by ICGA.
- ... and 5 more (see full listing online)

### Exclusion (27)

- Potential participants are excluded from the study if any of the following criteria apply:
- \[Ocular Conditions\] in the Study Eye
- Previous treatment with any anti-VEGF drugs or faricimab or investigational drugs at any time prior to Baseline.
- Previous use of intraocular or periocular steroids within the 6-month period prior to Baseline.
- Macular laser photocoagulation (focal/grid) or PDT at any time prior to Baseline and peripheral laser photocoagulation within 3 months prior to Baseline.
- ... and 22 more (see full listing online)

## Locations (1 total)

---

Yeungnam university medical center, Daegu, Namgu, South Korea

---

<https://clinicaltrials.gov/study/NCT07461441>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.